

EACR

European Association
for Cancer Research

CONFERENCES

www.eacr.org

EACR Conference

Cellular Bases for Patient Response to Cancer Therapies

14 - 16 November 2023 | Lyon, France

Scientific Programme Committee

Hugues de Thé (Chair),

Patrick Mehlen

Sophie Postel-Vinay

Scan the QR code to access online
conference resources, including speaker
and poster abstracts

www.eacr.org/conference/cellularbases2023



Save the date

eacr.org/conference



EACR-EMBO Conference

**COMMERCIALISING YOUR RESEARCH:
WHAT'S INVOLVED?**

Virtual event

30 - 31 January 2024

EACR

European Association
for Cancer Research

AACR

American Association
for Cancer Research

EACR-AACR Basic & Translational Research Conference

**HOW TO BRING BASIC SCIENCE
DISCOVERIES TO THE CLINIC**

27 - 29 Feb 2024
Dublin, Ireland

In partnership
with IACR



EACR Conference

THE TUMOUR ECOSYSTEM

Cellular Interactions and Therapeutic Opportunities

Bergamo, Italy

19 - 21 March 2024

EACR Conference

**CANCER MULTIOMICS &
COMPUTATIONAL BIOLOGY**

Bergamo, Italy

30 April - 02 May 2024

**EACR
2024**

10-13 June 2024
Rotterdam
Netherlands

Join us for the EACR
Annual Congress

2024.eacr.org

EACR Conference

CANCER METABOLISM

Bilbao Spain

08 - 10 October 2024

EACR Conference

LIQUID BIOPSIES

Lyon, France

12 - 14 November 2024

Cellular Bases for Patient Response to Cancer Therapies

#eacrCellularBases | WiFi: CELLULAR | Password: CELLULAR2023

Day 1 | Tuesday 14 November

From 11:30

REGISTRATION

All posters
can be put up

12:00 – 13:00

WELCOME LUNCH

A chance to meet fellow attendees and enjoy a light buffet lunch

13:00 – 13:10

CONFERENCE WELCOME

Scientific Programme Committee

SESSION 1: TECHNOLOGIES AND GENOMICS

Chair: Sophie Postel-Vinay

13:10 – 13:45

OPENING KEYNOTE LECTURE

Q&A: 13:45 – 13:55

Scott Lowe MSKCC, USA

"Understanding and exploiting tumor suppressive programs"

13:55 – 14:15

Céline Vallot Institut Curie, France

Q&A: 14:15 – 14:25

"Mechanisms of cell plasticity in breast cancers"

14:25 – 14:35

Mirja Rotinen Public University of Navarre, Spain

Q&A: 14:35 – 14:40

Proffered Paper 1: "ONECUT2 is a targetable lineage plasticity modulator of breast cancer that suppresses the estrogen axis"

14:40 – 14:50

EXHIBITOR INTRODUCTIONS

60-second intro pitches by each company

14:50 – 15:20

COFFEE BREAK & EXHIBITION

15:20 – 15:40

Jean Soulier Hôpital Saint-Louis, INSERM, France

Q&A: 15:40 – 15:50

"Secondary leukemia to stressed hematopoiesis"

15:50 – 16:10

Renata Basto Institut Curie, France

Q&A: 16:10 – 16:20

"Centrosome amplification induces apoptotic priming and favors the response to chemotherapy in epithelial ovarian cancer beyond multipolar divisions"

16:20 – 16:30

POSTER SPOTLIGHTS

Posters 11, 17, & 25 will be presented in short 3-minute 'flash talks'

16:30 – 17:00

MEET THE EXPERT SESSION

This informal and interactive session will be a great opportunity for participants to gain insight and advice from two of our outstanding speakers, Yves Pommier and Céline Vallot.

17:00 – 17:45



WELCOME RECEPTION

with drinks and a light buffet

17:45 – 19:15

POSTER DISCUSSION SESSION 1

Presenters of odd numbered posters should stand by their boards

Day 2 | Wednesday 15 November

08:30 – 09:00

POSTER VIEWING

09:00 – 09:20

Q&A: 09:20 – 09:30

SESSION 2: LEUKEMIA THERAPY

Chair: Patrick Mehlen

Andreas Trumpf DKFZ, Germany

"MAC-scoring in leukemic stem cells predicts response to Venetoclax in AML patients"

09:30 – 09:40

Q&A: 09:40 – 09:45

Irina Korovina HZDR, Germany

Proffered Paper 2: "Integrin $\alpha 2$ -deficiency reduces treatment resistance in glioblastoma by modulating ATF1 activity"

09:45 – 10:05

Q&A: 10:05 – 10:15

Hugues de Thé College de France, France

"From nuclear architecture to leukemia cure: emerging roles of PML"

10:15 – 10:35

Q&A: 10:35 – 10:45

Yves Pommier NCI, USA

"Genomics and Schlafen 11 (SLFN11) as predictors in oncology clinical trials"

10:45 – 11:15



COFFEE BREAK & EXHIBITION

11:15 – 11:35

Q&A: 11:35 – 11:45

Julien Ablain CRCL, France

"Investigating the mechanisms of melanoma development and therapy response using zebrafish"

11:45 – 11:55

Q&A: 11:55 – 12:00

Laura Broutier CRCL, France

Proffered Paper 3: "Modelling the next-generation of fusion-negative rhabdomyosarcoma 3D-organoids to predict effective drug combinations: a proof-of-concept on cell death inducers"

12:00 – 12:10

POSTER SPOTLIGHTS

Posters 24, 36, & 42 will be presented in short 3-minute 'flash talks'

12:10 – 13:10

LUNCH & EXHIBITION

13:10 – 14:40

POSTER DISCUSSION SESSION 2

Presenters of even numbered posters should stand by their boards

SESSION 3: NOVEL APPROACHES TO DRUG SENSITIVITY

Chair: Hugues de Thé

14:40 – 15:00

Q&A: 15:00 – 15:10

Sophie Postel-Vinay IGR, France

"Harnessing genetic vulnerabilities in immuno-oncology: novel therapeutic opportunities"

15:10 – 15:20

Q&A: 15:20 – 15:25

Mattia Marinucci University of Basel, Switzerland

Proffered Paper 4: "(Phospho)Proteomic analysis reveals vulnerabilities in metastatic colorectal cancer"

15:25 – 15:35

Q&A: 15:35 – 15:40

Hyunbin Huh Yonsei, South Korea

Proffered Paper 5: "Reprogramming anchorage dependency by adherent-to-suspension transition promotes metastatic dissemination"

15:40 – 16:00

Q&A: 16:00 – 16:10

Patrick Mehlen CRCL, France

"Targeting netrin-1 in cancer: from mechanisms of cell death to patients"

16:10 – 16:40

COFFEE BREAK & EXHIBITION

16:40 – 17:00

Q&A: 17:00 – 17:10

Fanny Jaulin Gustave Roussy, France

"Organoids as tools for functional precision medicine in advanced pancreatic cancer"

17:10 – 17:30

Q&A: 17:30 – 17:40

THE EMBO KEYNOTE LECTURE

Cedric Blanpain ULB, Belgium

"Targeting EMT mediated resistance to therapy"

17:40 – 18:40

PANEL DISCUSSION Chair: Hugues de Thé

Sophie Postel-Vinay, Patrick Mehlen, & Fanny Jaulin

This interactive session will provide a unique platform for attendees to exchange ideas and perspectives, to gain a comprehensive understanding of the evolving landscape of translational research on therapy responses, to connect for future collaborations.

19:30

OPTIONAL CONFERENCE DINNER

The 3-course dinner will be at the Hotel Crowne Plaza Lyon's restaurant, Bistrot Rive Gauche. Optional ticketed event.

Day 3 | Thursday 16 November

08:30 – 09:00

POSTER VIEWING

09:00 – 09:20

Q&A: 09:20 – 09:30

SESSION 4: METABOLISM AND SENESCENCE

Chair: Sophie Postel-Vinay

09:30 – 09:50

Q&A: 09:50 – 10:00

Filipe Cabriero MRC London Institute of Medical Sciences, UK

"Microbially derived adjuvants for cancer chemotherapy"

Jean-Emmanuel Sarry Oncopole, France

"Metabolic bases of drug resistance in acute myeloid leukemia"

10:00 – 10:10

Q&A: 10:10 – 10:15

Rocio Matesanz Sanchez OncoRay, Germany

Proffered Paper 6: "Targeting exostosin glycosyltransferase 2 (EXT2) modulates glioblastoma cell metabolism, sensitizing to X-ray irradiation via ferroptosis"

10:15 – 10:45



COFFEE BREAK & EXHIBITION

10:45 – 11:05

Q&A: 11:05 – 11:15

Geraldine Gentric Institut Curie, France

"Role of stromal heterogeneity in resistance to treatments"

11:15 – 11:50

Q&A: 11:50 – 12:00

CLOSING KEYNOTE LECTURE

Clemens Schmitt Max Delbrück Center, Germany

"Apoptosis-competent anticancer treatment failure"

12:00

SUMMARY, AWARDS & DEPART

Travel Grants

More information about EACR grants: eacr.org/travel-grant

EACR-Worldwide Cancer Research Travel Grants provide funds to help early-career EACR members and researchers based in low- or middle-income economy countries to participate in our conferences.

Congratulations to the recipients of the Travel Grants for this conference. Each recipient received a full registration free of charge and funds to assist with travel and accommodation costs.

- **DAVID HACKETT** IRELAND
- **SAMEER KUMAR PANDA** ITALY
- **ANXO RÍO VILARIÑO** SPAIN
- **DANIELA SCHULZ** GERMANY
- **GIZEM YALÇIN** TURKEY

EACR

European Association
for Cancer Research

**worldwide
cancer
research**

Supporters

We would like to thank the following grant providers:



This activity has been supported by a grant from F. Hoffman-La Roche Ltd, which has had no control over the educational content of this activity.

Our thanks also to the following partners for supporting us in promoting this conference:



CENTRE DE
RECHERCHE EN
CANCEROLOGIE
DE LYON



The future of cancer therapy




Life Science Alliance

PLOS COMPUTATIONAL BIOLOGY



The Video Journal of Oncology

Venue Floor Plan



Meet the Exhibitors

SB-PEPTIDE Stand: 1

Website: www.sb-peptide.com

Represented at the conference by:

Aurélien Claeysen



InSCREENeX Stand: 2

Website: www.inscreenex.de

Represented at the conference by:

Tobias May, Kristina Nehlsen



MedChemExpress Stand: 3

Website: www.medchemexpress.com

Represented at the conference by:

Inès Hoang, Myriam Loukrik, Johnny Truong



Don Whitley Scientific Stand: 4

Website: www.dwscientific.com

Represented at the conference by:

Alun Kitsell, Christophe Salgueiro



Cancer Research Centre of Lyon Stand: 5

Website: www.crcl.fr

Represented at the conference by:

Quynh Chuong



VectorBuilder Stand: 6

Website: en.vectorbuilder.com

Represented at the conference by:

Gaetan Domin



Nonacus Stand: 7

Website: nonacus.com

Represented at the conference by:

Elodie Desmaris



Poster Index

View abstracts when logged-in at www.eacr.org/conference/cellularbases2023

1 Molecular portrait of hormone therapy-resistant and sensitive breast cancer patients Presented by Suhail Ahmad, Advanced Centre for Treatment, Research and Education in Cancer & Homi Bhabha National Institute, Mumbai, INDIA

2 The anterior gradient homologue 2 (AGR2) co-localises with the glucose-regulated protein 78 (GRP78) in cancer stem cells, and is critical for the survival and drug resistance of recurrent glioblastoma: in situ and in vitro analyses Presented by Reem Alsereihi, Alayna Colleges, Madina & King Fahd Center for Medical Research, Jeddah, SAUDI ARABIA

3 Pancreatic stellate cell-induced gemcitabine resistance in pancreatic cancer is associated with enhanced glycolysis Presented by Manoj Amrutkar, Oslo University Hospital Rikshospitalet, NORWAY

4 Responses to cellular stress analyzed by quantitative phase microscopy Presented by Miguel Arocena, Universidad de la República, Montevideo, URUGUAY

5 PD-L1 Knockout Suppresses TNBC Cell Proliferation, Migration, Invasion, and Tumor Growth: Unveiling Therapeutic Opportunities through Signaling Pathway Analysis Presented by Samir Attoub, United Arab Emirates University, AI AIN, UNITED ARAB EMIRATES

6 Evaluation of Potential Anticarcinogenic Effects of Liposomal Prodrug SN38-Oleic Acid on Triple Negative Breast Cancer Cells Presented by Rümeyza Fatma Balaban, Uludag University, Bursa, TURKEY

7 Crosstalk between melanosomes and mitochondria: a new druggable interface for metastatic melanoma Presented by Caterina Baldanzi, CNR & CRL-ISPRO, Pisa, ITALY

8 Myxofibrosarcoma cell lines derived from primary tumor or recurrence show different sensitivity to photodynamic therapy Presented by Chiara Bellotti, IRCCS Istituto Ortopedico Rizzoli, Bologna, ITALY

9 Virotherapy for Triple-Negative Breast Cancer Presented by Olga Bezborodova, Ministry of Health of the Russian Federation, Moscow, RUSSIAN FEDERATION

10 Mitochondrial metabolic alterations contributes to imatinib-resistance in chronic myeloid leukemia cell line Presented by Manish Bhat, ACTREC & Homi Bhabha National Institute, Mumbai, INDIA

11 **[POSTER SPOTLIGHT]** In-depth phosphoproteomics reveals novel mechanisms of tyrosine kinase inhibitor resistance in chronic myeloid leukemia Presented by Valeria Bica, University of Rome, ITALY

12 Next generation proteomics identifies a potential protein marker of poor response to tyrosine kinase inhibitors in metastatic renal cell carcinoma Presented by Pavla Bouchalova, Masaryk University, Brno, CZECH REPUBLIC

- 13 Combination of Remdesivir and Quercetin in TNBC Cells Regulates the EMT Pathway Presented by Ebrucan Bulut, Bursa Uludag University, TURKEY
- 14 Unleashing the Immune System Against Triple Negative Breast Cancer Through Inactivation of the Hsp90 Chaperoning Machine Presented by Ahmed Chadli, Georgia Cancer Center at Augusta University, Georgia, USA
- 15 p53 pathway reactivation selectively impairs viability of aggressive Ewing's sarcoma stem-like cells Presented by Lucie Curylova, Masaryk University & International Clinical Research Center, St. Anne's University Hospital, Brno, CZECH REPUBLIC
- 16 Innovative 3D models to characterise the interplay of integrins adhesion receptors and ion channels in the crosstalk between Pancreatic Ductal AdenoCarcinoma (PDAC) cell lines and Tumour MicroEnvironment (TME) Presented by Franco Nicolás D'Alessandro, University of Siena & University of Florence, ITALY
- 17 **[POSTER SPOTLIGHT]** A novel combinatorial therapy improves the outcome of infant t(4;11) pro-B-ALL by reverting epigenetic repression of HDAC7 biomarker Presented by Oriol de Barrios Barri, Josep Carreras Leukaemia Research Institute, Badalona, SPAIN
- 18 Targeting BRD9 as a Potential Therapy Approach for Glioblastoma Presented by Nareg Degirmenci, Koç University Research Center for Translational Medicine, Istanbul, TURKEY
- 19 Identification and validation of potent inducers of breast cancer stem cell differentiation Presented by Monica Fedele, IEO, CNR, Naples, ITALY
- 20 Establishment of ex-vivo tissue culture model for preclinical hepatocellular carcinoma treatment and hepatotoxicity evaluation Presented by Huiche Feng, University Hospital Basel, SWITZERLAND
- 21 Harnessing mesenchymal stem cells-Mediated Tumor Microenvironment Perturbation for Enhanced Chemiosensitivity: proposing a preclinical study as a step towards clinical implementation of a promising hypothesis Presented by Benedetta Ferrara, IRCCS San Raffaele, Milano, ITALY
- 22 In vitro and in vivo characterization of the combinatorial effect of Axitinib and N-acetyl cysteine treatment in glioblastoma Presented by Alessia Formato, IBBC-CNR, Rome, ITALY
- 23 Screening of FDA-approved drug library with an oncolytic vesicular stomatitis virus identifies novel candidate combinatorial treatments for pancreatic cancer Presented by Valery Grdzlishvili, University of North Carolina at Charlotte, USA
- 24 **[POSTER SPOTLIGHT]** FAO-supported OxPhos leukemic stem cells are sensitive to cold Presented by Emmanuel Griessinger, Université Côte d'Azur, Nice, FRANCE & University of Groningen, NETHERLANDS
- 25 **[POSTER SPOTLIGHT]** A chemical suppressor screening in zebrafish identifies Wnt/-catenin pathway inhibitors improving anticancer drug response. Presented by Naoyuki Nishiya, Iwate Medical University, Shiwa-gun, JAPAN

- 26 Targeting the miR-31-ATOX1-drug trafficking axis to enhance chemosensitivity of pancreatic ductal adenocarcinoma. Presented by David Hackett, Trinity College Dublin, IRELAND
- 27 Frequent inactivation of tumor suppressor genes is associated with early acquired resistance to EGFR inhibitors in lung adenocarcinoma Presented by Supriya Hait, ACTREC & Homi Bhabha National Institute, Mumbai, INDIA
- 28 Looking for roles beyond DNA repair for XPF and SLX4 proteins in cancer cells Presented by Lars Petter Jordheim, CRCL, Lyon, FRANCE
- 29 Ex vivo modified extracellular vesicles as immune cell stimulators Presented by Klaudia Kiel, Mossakowski Medical Research Institute Polish Academy of Sciences, Warsaw, POLAND
- 30 Cyclosporin A inhibits prostate cancer growth through suppression of E2F8 Presented by Da young Lee, Seoul National University College of Medicine, SOUTH KOREA
- 31 Nutlin-3a-loaded ethosomes as a delivery system in vitro to target p53 in melanoma Presented by Giada Lodi, University of Ferrara, ITALY
- 32 ANGPTL4: A critical regulator of the proinflammatory secretome of senescent cells and of cancer initiation Presented by Gabriela Makulyte, Lyon University & Equipe Labellisée la Ligue Contre le Cancer, Lyon, FRANCE
- 33 Metastases of colorectal cancer deserve their own classification and tailored therapies Presented by Emilie Mamessier, CRCM -Inserm U1068 & Institut Paoli Calmettes, Marseille, FRANCE
- 34 Retinoic acid and proteotoxic stress induce AML cell death overcoming stromal cell protection Presented by Silvia Masciarelli, Sapienza University of Rome, ITALY
- 35 Deciphering Mutant p53-PIK3CA Nexus: Opportunities for Targeted Therapy in High-Grade Serous Ovarian Cancer Presented by Megha Mehrotra, ACTREC & Homi Bhabha National Institute, Mumbai, INDIA
- 36 **[POSTER SPOTLIGHT]** The effect of PM2.5 in human lung cancer cells with a microfluidic platform Presented by Thi Nhat Uyen Nguyen, ICPTRM/Taipei medical university, TAIWAN
- 37 Mitochondrial trafficking from MSC to cancer cells in the tumor microenvironment (TME) regulating breast cancer drug resistance Presented by Sameer Kumar Panda, University of Campania "Luigi Vanvitelli", Naples, ITALY & University of South Australia and SA Pathology, Adelaide, AUSTRALIA
- 38 AURKA Inhibition Restores Cetuximab Efficacy via YAP1/TAZ Suppression Presented by Anxo Río Vilariño, Instituto de Investigaciones Sanitarias Fundación Jiménez Díaz, Madrid, SPAIN
- 39 Intracellular PD-L1 trafficking and response to irradiation in head and neck cancer Presented by Sophia Rohrmüller, University Hospital Regensburg, GERMANY

- 40 *Asparagus officinalis* L. aqueous extracts mediate cell cycle block and migration inhibition in breast cancer cells Presented by Arianna Romani, University of Ferrara & LTTA Centre, Ferrara, ITALY
- 41 The role of tumor-derived extracellular vesicles in modulating neutrophils towards a pro-tumor angiogenic state in head and neck squamous cell carcinoma Presented by Dominique Rubenich, Universidade Federal de Ciências da Saúde de Porto Alegre, BRAZIL & University Hospital Regensburg, GERMANY
- 42 **[POSTER SPOTLIGHT]** Understanding and exploiting chemotherapy metabolism – targeting the dNTP hydrolase SAMHD1 Presented by Sean Rudd, SciLifeLab & Karolinska Institutet, Stockholm, SWEDEN
- 43 Regorafenib in glioblastoma: in vitro characterization of tumor cells response Presented by Maria Salbini, IBBC-CNR, Rome, ITALY
- 44 PD-L1 in Head and Neck Cancer: Much more than just an immune regulatory protein Presented by Daniela Schulz, Department of Oral and Maxillofacial Surgery, Regensburg, GERMANY
- 45 Understanding CDK4/6 inhibitor resistance: The cell cycle position matters Presented by Xu Shen, University College London, UK
- 46 Ginsenoside compound K induces ferroptosis via Nur77 under hypoxic microenvironment Presented by Zeyu Shi, University of Hong Kong & Laboratory for Synthetic Chemistry and Chemical Biology Limited, Hong Kong, P.R. CHINA
- 47 Characterization of Non-Small Cell Lung Cancer (NSCLC) Akt's Molecular Changes Using an Air-Liquid (ALI) Culture Approach Presented by Carolina Sousa, University of Lisbon, PORTUGAL
- 48 Circular MALAT1 – the new kid on the block in breast-to-brain metastatic cancer Presented by Adrian Szczepaniak, Mossakowski Medical Research Institute, Polish Academy of Sciences, Warsaw, POLAND
- 49 Mitochondrial DNA mutations in ovarian cancer and their impact on the response to anti-VEGF therapy in PDX models Presented by Chiara Trento, University of Padova, ITALY
- 50 Finding Therapy-Induced Vulnerabilities in Patient-Derived Organoids Established from Metastatic Colorectal Cancer via High-throughput-3D-Imaging of Drug Screening Presented by Gizem Yalçın, Middle East Technical University, Ankara, TURKEY
- 51 TELO2, a regulator of phosphatidylinositol 3-kinase-related kinases, is a druggable target for an inhibitor of the Wnt/-catenin and the mTOR signaling Presented by Honami Yonezawa, Iwate Medical University, Shiwa-gun, JAPAN
- 52 CONCEPT: a study for multiomic characterization of hepatobiliary cancers Presented by Michele Zanoni, IRCCS, IRST, Meldola, ITALY
- 53 Development of the first PROTACs targeting nuclear BRAFV600E in cancer Presented by Mourad Zerfaoui, Tulane University, New Orleans, USA

Communication.
Collaboration.
Community.

EACR

European Association
for Cancer Research



**NOT A MEMBER
YET? JOIN NOW**

Apply for funding
to develop your
research &
expand
your
horizons



Benefit from
member
registration
rates at EACR
events

Join our
Science Book
Club on
LinkedIn



Build new
connections
with our 'Find a
Collaborator'
tool

Search
the EACR
Member
Network
and message
other members



Share your
perspective: write
for The Cancer
Researcher
magazine

Access
our free
expert
webinars on
research &
careers



Stay informed
with regular
updates on
news, jobs &
conferences

Volunteer for
our Ambassador
Programme or
committees

EACR on-site team



Hannah Barrs
Conference Officer



Kathryn Wass
Programmes Manager



Steph Milsom
Marketing Officer



Alexandra Boitor
Scientific Officer

Conference Dinner

Optional Ticketed Event: Wednesday 15 November, 19:30

The Conference Dinner will take place on the final night of the meeting. It will be an excellent opportunity for participants and speakers to get to know each other in a relaxed and informal environment.

The dinner is being held at the Hotel Crowne Plaza Lyon in their restaurant Bistrot Rive Gauche, located a short walk from the Centre de Congrès de Lyon.

Venue

Bistrot Rive Gauche
Crowne Plaza Lyon – Cite
Interationale
22 Quai Charles de Gaulle
Lyon 69 006

Tickets for the conference dinner are not included in the registration fee.



EACR Industry Partners

The European Association for Cancer Research gratefully acknowledges its Industry Partners, who offer ongoing support to the EACR and provide the means for the Association to develop important initiatives.

